Duke professor-led biotech company raises $175 million to advance epigenome editing therapy clinical trials
By Srilakshmi Venkatesan | January 31, 2025The company will use the funding to advance clinical trials for Tune-401, the epigenetic silencing drug for treating chronic Hepatitis B — a viral infection that damages the liver and affects millions globally.